32560

Chemical Pleurodesis via Chest Tube

Chemical pleurodesis is a therapeutic medical procedure performed to obliterate the pleural space, thereby preventing the recurrent accumulation of air (pneumothorax) or fluid (pleural effusion). The procedure is most commonly indicated for patients with malignant pleural effusions or recurrent spontaneous pneumothoraces who are not candidates for more invasive surgical interventions. During the procedure, a sclerosing agent—such as sterile talc slurry, doxycycline, or bleomycin—is instilled into the pleural cavity through a pre-existing or newly placed chest tube (thoracostomy tube). The mechanism of action involves the induction of a controlled chemical pleuritis, which triggers an inflammatory response. This inflammation promotes the formation of fibrous adhesions between the visceral and parietal pleurae, effectively fusing the two layers together and eliminating the potential space. For the procedure to be successful, the lung must be capable of fully expanding to achieve apposition of the pleural surfaces; 'trapped lung' is a common contraindication. Following the instillation of the sclerosant, the chest tube is often clamped for a period, and the patient may be repositioned (rotated) to ensure the chemical agent reaches all surfaces of the pleural cavity, although recent clinical evidence suggests that rotation may not always be strictly necessary. The chest tube is later returned to suction or water seal to drain any remaining fluid and ensure continued pleural contact while the adhesions form. This procedure is instrumental in improving the quality of life for palliative care patients by reducing dyspnea and the need for frequent thoracentesis.

Clinical Indications

  • Recurrent spontaneous pneumothorax
  • Persistent air leak following chest tube insertion for pneumothorax
  • Malignant pleural effusion (e.g., secondary to lung or breast cancer)
  • Chronic or symptomatic pleural effusion refractory to medical management
  • Prevention of recurrent pneumothorax in patients with significant underlying lung disease (e.g., COPD/Emphysema)

Procedure Steps

  1. Verify the correct patient identity and procedural site.
  2. Ensure the existing chest tube is properly positioned and the lung is fully expanded on chest X-ray.
  3. Administer adequate analgesia or local anesthesia, as the chemical inflammation can cause significant pleuritic pain.
  4. Prepare the sclerosing agent (e.g., mixing sterile talc with saline to create a slurry).
  5. Instill the sclerosing agent into the pleural space via the chest tube using a large-bore syringe.
  6. Flush the chest tube with a small amount of saline to ensure the entire dose of the sclerosant has entered the pleural space.
  7. Clamp the chest tube for a specified period (typically 1 to 2 hours) or keep it elevated to prevent immediate drainage.
  8. Optionally reposition the patient (supine, lateral decubitus, prone) to distribute the sclerosant.
  9. Unclamp the tube and return it to suction or a drainage system to remove excess fluid and maintain pleural apposition.
  10. Perform follow-up imaging (chest X-ray) to monitor lung expansion and fluid levels.

Coding Guidelines

  • CPT code 32560 describes the instillation of the sclerosant only.
  • If a chest tube is inserted during the same session, it should be reported separately using code 32551 (Tube thoracostomy).
  • If the procedure is performed bilaterally, append modifier -50 to code 32560.
  • Do not report 32560 in conjunction with VATS pleurodesis (32650), as the surgical approach includes the pleurodesis.
  • For the administration of a chemotherapeutic agent for cytotoxic effect rather than sclerosis, see code 96446.
  • The sclerosing agent itself (the medication/substance) may be reported separately using the appropriate HCPCS Level II code (e.g., J3305 for sterile talc powder).

Associated ICD-10 Codes